港股异动 | 再鼎医药(09688)涨超4% 宣布与勃林格殷格翰合作开发创新双DLL3靶向药物联合疗法_老虎社区_美港股上老虎

港股异动 | 再鼎医药(09688)涨超4% 宣布与勃林格殷格翰合作开发创新双DLL3靶向药物联合疗法

智通财经04-16

智通财经APP获悉，再鼎医药(09688)涨超4%，截至发稿，涨3.84%，报18.1港元，成交额8271.49万港元。消息面上，4月15日，据再鼎医药官微消息，公司与勃林格殷格翰宣布一项临床合作，着力开发一种创新的双DLL3靶向药物联合疗法。Ib/II期研究将评估再鼎医药的靶向DLL3的ADC zocilurtatug pelitecan(zoci，原名ZL-1310)与勃林格殷格翰的DLL3/...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Blackland
·04-16
没用
回复
1
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2627025713?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-16 10:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627025713","market":"fut","top_or_hot":-1,"title":"港股异动 | 再鼎医药(09688)涨超4% 宣布与勃林格殷格翰合作开发创新双DLL3靶向药物联合疗法","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，再鼎医药(09688)涨超4%，截至发稿，涨3.84%，报18.1港元，成交额8271.49万港元。消息面上，4月15日，据再鼎医药官微消息，公司与勃林格殷格翰宣布一项临床合作，着力开发一种创新的双DLL3靶向药物联合疗法。Ib/II期研究将评估再鼎医药的靶向DLL3的ADC zocilurtatug pelitecan(zoci，原名ZL-1310)与勃林格殷格翰的DLL3/...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1429188.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 再鼎医药(09688)涨超4% 宣布与勃林格殷格翰合作开发创新双DLL3靶向药物联合疗法</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 再鼎医药(09688)涨超4% 宣布与勃林格殷格翰合作开发创新双DLL3靶向药物联合疗法\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-16 10:09 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1429188.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，再鼎医药(09688)涨超4%，截至发稿，涨3.84%，报18.1港元，成交额8271.49万港元。消息面上，4月15日，据再鼎医药官微消息，公司与勃林格殷格翰宣布一项临床合作，着力开发一种创新的双DLL3靶向药物联合疗法。Ib/II期研究将评估再鼎医药的靶向DLL3的ADC zocilurtatug pelitecan(zoci，原名ZL-1310)与勃林格殷格翰的DLL3/...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1429188.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZLAB","symbol_name":"再鼎医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1429188.html","article_id":"2627025713","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627025713","pubTimestamp":1776305396,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，再鼎医药涨超4%，截至发稿，涨3.84%，报18.1港元，成交额8271.49万港元。消息面上，4月15日，据再鼎医药官微消息，公司与勃林格殷格翰宣布一项临床合作，着力开发一种创新的双DLL3靶向药物联合疗法。Ib/II期研究将评估再鼎医药的靶向DLL3的ADC zocilurtatug pelitecan与勃林格殷格翰的DLL3/CD3 T细胞衔接器obrixtamig联合使用的安全性、耐受性及初步临床活性。据介绍，Zocilurtatug pelitecan是再鼎医药开发的一款靶向DLL3的ADC，旨在向DLL3阳性肿瘤细胞递送强效细胞毒性载荷，用于ES-SCLC治疗。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ZLAB":"再鼎医药","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4548":"巴美列捷福持仓","BK4531":"中概回港概念","VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","BK1574":"生物医药B类股","09688":"再鼎医药","BK4585":"ETF&股票定投概念","BK1588":"回港中概股","BK4526":"热门中概股","BK1161":"生物科技","BK4139":"生物科技"},"translate_title":"Hong Kong stock changes | Zai Lab (09688) rose more than 4% and announced cooperation with Boehringer Ingelheim to develop innovative dual-DLL3 targeted drug combination therapy","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":1.5,"VXUS":1.5,"ZLAB":1.5},"content_text":"智通财经APP获悉，再鼎医药(09688)涨超4%，截至发稿，涨3.84%，报18.1港元，成交额8271.49万港元。消息面上，4月15日，据再鼎医药官微消息，公司与勃林格殷格翰宣布一项临床合作，着力开发一种创新的双DLL3靶向药物联合疗法。Ib/II期研究将评估再鼎医药的靶向DLL3的ADC zocilurtatug pelitecan(zoci，原名ZL-1310)与勃林格殷格翰的DLL3/CD3 T细胞衔接器obrixtamig联合使用的安全性、耐受性及初步临床活性。据介绍，Zocilurtatug pelitecan(简称zoci)是再鼎医药开发的一款靶向DLL3的ADC，旨在向DLL3阳性肿瘤细胞递送强效细胞毒性载荷，用于ES-SCLC治疗。最新全球I期结果显示，zoci在既往接受治疗后的ES-SCLC患者，包括在脑转移患者中，表现出强效且持久的缓解，同时具有良好的安全性。在此基础上，该项目已进入全球III期注册性研究。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[{"id":554092852535728,"gmtCreate":1776311141636,"gmtModify":1776311144200,"author":{"id":"4160227637143462","authorId":"4160227637143462","name":"Blackland","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"wearingBadges":[{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","name":"博闻投资者","description":"累计交易超过10只正股","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}],"idStr":"4160227637143462","authorIdStr":"4160227637143462"},"htmlText":"没用","listText":"没用","text":"没用","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/554092852535728","repostId":2627025713,"repostType":2,"repost":{"id":"2627025713","kind":"news","pubTimestamp":1776305396,"share":"https://www.laohu8.com/m/news/2627025713?lang=zh_CN&edition=full","pubTime":"2026-04-16 10:09","market":"fut","language":"zh","title":"港股异动 | 再鼎医药(09688)涨超4% 宣布与勃林格殷格翰合作开发创新双DLL3靶向药物联合疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2627025713","media":"智通财经","summary":"智通财经APP获悉，再鼎医药涨超4%，截至发稿，涨3.84%，报18.1港元，成交额8271.49万港元。消息面上，4月15日，据再鼎医药官微消息，公司与勃林格殷格翰宣布一项临床合作，着力开发一种创新的双DLL3靶向药物联合疗法。Ib/II期研究将评估再鼎医药的靶向DLL3的ADC zocilurtatug pelitecan与勃林格殷格翰的DLL3/CD3 T细胞衔接器obrixtamig联合使用的安全性、耐受性及初步临床活性。据介绍，Zocilurtatug pelitecan是再鼎医药开发的一款靶向DLL3的ADC，旨在向DLL3阳性肿瘤细胞递送强效细胞毒性载荷，用于ES-SCLC治疗。","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/ZLAB\">再鼎医药</a>(09688)涨超4%，截至发稿，涨3.84%，报18.1港元，成交额8271.49万港元。</p><p>消息面上，4月15日，据<a href=\"https://laohu8.com/S/09688\">再鼎医药</a>官微消息，公司与勃林格殷格翰宣布一项临床合作，着力开发一种创新的双DLL3靶向药物联合疗法。Ib/II期研究将评估再鼎医药的靶向DLL3的ADC zocilurtatug pelitecan(zoci，原名ZL-1310)与勃林格殷格翰的DLL3/CD3 T细胞衔接器obrixtamig联合使用的安全性、耐受性及初步临床活性。</p><p>据介绍，Zocilurtatug pelitecan(简称zoci)是再鼎医药开发的一款靶向DLL3的ADC，旨在向DLL3阳性肿瘤细胞递送强效细胞毒性载荷，用于ES-SCLC治疗。最新全球I期结果显示，zoci在既往接受治疗后的ES-SCLC患者，包括在脑转移患者中，表现出强效且持久的缓解，同时具有良好的安全性。在此基础上，该项目已进入全球III期注册性研究。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 再鼎医药(09688)涨超4% 宣布与勃林格殷格翰合作开发创新双DLL3靶向药物联合疗法</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 再鼎医药(09688)涨超4% 宣布与勃林格殷格翰合作开发创新双DLL3靶向药物联合疗法\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-16 10:09 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1429188.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，再鼎医药(09688)涨超4%，截至发稿，涨3.84%，报18.1港元，成交额8271.49万港元。消息面上，4月15日，据再鼎医药官微消息，公司与勃林格殷格翰宣布一项临床合作，着力开发一种创新的双DLL3靶向药物联合疗法。Ib/II期研究将评估再鼎医药的靶向DLL3的ADC zocilurtatug pelitecan(zoci，原名ZL-1310)与勃林格殷格翰的DLL3/...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1429188.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZLAB":"再鼎医药","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4548":"巴美列捷福持仓","BK4531":"中概回港概念","VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","BK1574":"生物医药B类股","09688":"再鼎医药","BK4585":"ETF&股票定投概念","BK1588":"回港中概股","BK4526":"热门中概股","BK1161":"生物科技","BK4139":"生物科技"},"source_url":"http://www.zhitongcaijing.com/content/detail/1429188.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2627025713","content_text":"智通财经APP获悉，再鼎医药(09688)涨超4%，截至发稿，涨3.84%，报18.1港元，成交额8271.49万港元。消息面上，4月15日，据再鼎医药官微消息，公司与勃林格殷格翰宣布一项临床合作，着力开发一种创新的双DLL3靶向药物联合疗法。Ib/II期研究将评估再鼎医药的靶向DLL3的ADC zocilurtatug pelitecan(zoci，原名ZL-1310)与勃林格殷格翰的DLL3/CD3 T细胞衔接器obrixtamig联合使用的安全性、耐受性及初步临床活性。据介绍，Zocilurtatug pelitecan(简称zoci)是再鼎医药开发的一款靶向DLL3的ADC，旨在向DLL3阳性肿瘤细胞递送强效细胞毒性载荷，用于ES-SCLC治疗。最新全球I期结果显示，zoci在既往接受治疗后的ES-SCLC患者，包括在脑转移患者中，表现出强效且持久的缓解，同时具有良好的安全性。在此基础上，该项目已进入全球III期注册性研究。","news_type":1,"symbols_score_info":{"09688":1.5,"VXUS":1.5,"ZLAB":1.5}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}